DDInter1042 DDInter77
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys.
Amisulpride {u} (Compound) resembles {v} (Compound) Alizapride
Amisulpride {u} (Compound) binds {v} (Gene) HTR7
Amisulpride {u} (Compound) upregulates {v} (Gene) RGS2
Amisulpride {u} (Compound) causes {v} (Side Effect) Urticaria
Amisulpride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin Immune Fab (Ovine)
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Promethazine
Amisulpride {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Amisulpride (Compound) resembles Alizapride (Compound)
Amisulpride (Compound) binds HTR7 (Gene)
Amisulpride (Compound) upregulates RGS2 (Gene)
Amisulpride (Compound) causes Urticaria (Side Effect)
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Digoxin Immune Fab (Ovine)
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Amisulpride may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Promethazine
Amisulpride (Compound) resembles Metoclopramide (Compound) and Amisulpride may lead to a major life threatening interaction when taken with Metoclopramide